STOCK TITAN
  1. Home
  2. News
  3. COGT

Cogent Biosciences Inc - COGT STOCK NEWS

Welcome to our dedicated news page for Cogent Biosciences (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cogent Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cogent Biosciences's position in the market.

News
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Rhea-AI Summary
Cogent Biosciences, Inc. (Nasdaq: COGT) announces new preclinical data on its ErbB2 inhibitor program at AACR 2024, expecting to start IND-enabling studies in mid-2024. The data highlights the potential of a brain-penetrant ErbB2 inhibitor with promising characteristics for rare disease populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
none
-
News
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Cogent Biosciences, Inc. provides a business update and financial results for Q4 and full year 2023. The company is actively enrolling three registration-directed clinical trials for bezuclastinib, with promising results. The pro-forma cash of $487 million ensures funding until 2027. Key milestones include topline results expected by YE 2025 for various studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
earnings
-
News
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Rhea-AI Summary
Cogent Biosciences reports positive data from SUMMIT trial on bezuclastinib for NonAdvSM patients at AAAAI meeting. Part 2 initiated with encouraging results. Safety and tolerability profile reported. Investor webcast scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
News
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
Rhea-AI Summary
Cogent Biosciences, Inc. announces a private investment in public equity financing expected to raise approximately $225 million, positioning the company well financially through 2027. The financing, led by Commodore Capital and a large investment management firm, includes both new and existing investors. The company plans to use the funds to advance bezuclastinib through ongoing clinical trials and aims to establish it as a leading KIT mutant inhibitor for systemic mastocytosis and gastrointestinal stromal tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.34%
Tags
none
-
News
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Rhea-AI Summary
Cogent Biosciences, Inc. (Nasdaq: COGT) will present posters for bezuclastinib at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting and host a virtual investor webcast on February 23 at 8:00 a.m. ET. The posters will feature initial results from the SUMMIT Phase 2 clinical study of Bezuclastinib and perspectives on relevant symptoms of Non-Advanced Systemic Mastocytosis. The webcast will discuss the SUMMIT Part 1b data led by Andrew Robbins, Cogent’s President and CEO, and include a presentation by PD Dr. Frank Siebenhaar, M.D., Head University Outpatient Clinic, Institute of Allergology, Charité - Universitätsmedizin Berlin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
conferences
-
News
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Rhea-AI Summary
Cogent Biosciences, a biotechnology company focused on precision therapies for genetically defined diseases, highlighted key 2024 milestones at J.P. Morgan's 42nd annual healthcare conference. The company plans to complete enrollment in pivotal Phase 3 PEAK study of bezuclastinib + sunitinib, initiate Phase 2 APEX study of bezuclastinib, and present results from the complete SUMMIT Part 1 at 2024 AAAAI annual conference. Cogent also aims to initiate a Phase 1 trial of CGT4859, a potential FGFR2 inhibitor, in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
acquisition
News
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Cogent Biosciences, Inc. (Nasdaq: COGT) to present at 42nd Annual J.P. Morgan Healthcare Conference. President and CEO, Andrew Robbins, to speak on precision therapies for genetically defined diseases. Webcast available on investors.cogentbio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
none
-
News
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Rhea-AI Summary
Cogent Biosciences, Inc. (Nasdaq: COGT) reported positive data from Part 1 of the ongoing Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The trial showed a 56% overall response rate (ORR) in TKI-naïve patients, including an 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose. The safety and tolerability profile was encouraging with no related cognitive impairment or bleeding events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.01%
Tags
clinical trial
-
News
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Rhea-AI Summary
Cogent Biosciences, Inc. (Nasdaq: COGT) reported positive initial data from the ongoing Phase 2 SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM) at the 65th American Society of Hematology (ASH 2023) Annual Meeting & Exposition. The trial demonstrated rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20. 100% of bezuclastinib treated patients achieved at least 50% improvement across all relevant biomarker measures, with a safety and tolerability profile supporting potential for chronic dosing. The company plans to advance into Part 2 of SUMMIT, a registration-directed, global, randomized placebo-controlled trial, and present additional data from SUMMIT in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
Rhea-AI Summary
Cogent Biosciences, a biotechnology company (Nasdaq: COGT), presented updated preclinical data on its potent, selective, and brain-penetrant ErbB2 inhibitor program and initial preclinical data from its newly disclosed H1047R mutant-selective PI3Kα inhibitor discovery program at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
clinical trial
Stock COGT logo
Cogent Biosciences Inc

Nasdaq:COGT

COGT Rankings

#2707 Ranked by Market Cap
#4308 Ranked by Stock Gains
N/A Ranked by Dividends

COGT Stock Data

622.44M
80.04M
0.14%
100.15%
11.34%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About COGT

unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act